BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28813246)

  • 1. The benefits of data mining.
    Bone A; Houck K
    Elife; 2017 Aug; 6():. PubMed ID: 28813246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
    Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
    Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
    [No Abstract]   [Full Text] [Related]  

  • 4. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
    Min J; Osborne V; Kowalski A; Prosperi M
    Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
    Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
    Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
    Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
    Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the adverse events of Aristadaļ¼šA real-world study based on FAERS database.
    Ou M; Zhou Q; Zhu H; Du Z; Shen Y; Luan P; Jiang Y
    Asian J Psychiatr; 2024 Apr; 94():103968. PubMed ID: 38354623
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
    Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
    Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy.
    Wang X; Zhang P; Chiang CW; Wu H; Shen L; Ning X; Zeng D; Wang L; Quinney SK; Feng W; Li L
    Stat Med; 2018 Feb; 37(4):673-686. PubMed ID: 29171062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 15. AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System.
    Grigoriev I; zu Castell W; Tsvetkov P; Antonov AV
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):795-801. PubMed ID: 24677538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions.
    Roswell R; Van Diepen LR; Jones JK; Hicks WE
    Lancet; 2001 Feb; 357(9255):561-2. PubMed ID: 11229704
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

  • 19. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants.
    Wong CK; Ho SS; Saini B; Hibbs DE; Fois RA
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):731-7. PubMed ID: 26017154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.